Longevity & Healthspan: A Functional Medicine Approach

Introduction: The Gap Nobody Talks About

Global life expectancy has risen dramatically over the past century — from an average of 47 years in 1900 to 73 years today, according to the World Health Organisation. This is one of modern medicine's great achievements. But it comes with an uncomfortable reality that is increasingly central to clinical practice: the years we have gained are not, on average, healthy years.

The World Health Organisation estimates the global average healthspan — the period of life spent in good health, free from significant disease or disability — at approximately 63 years. That leaves a gap of roughly a decade during which many people are alive but not well: living with chronic disease, cognitive decline, reduced mobility, pain and loss of independence. In Ireland, this picture is consistent with European trends, with the average healthy life years at birth running approximately 10–12 years behind total life expectancy.^[1]

Longevity medicine — as a clinical and scientific discipline — exists to address that gap. Not simply to extend lifespan, but to extend healthspan: the quality, vitality and function of the years lived. This is the distinction that separates the longevity medicine movement from anti-ageing marketing, and it is the distinction that makes it directly relevant to functional medicine clinical practice.

Where This Trend Came From

The longevity medicine movement did not emerge from a single discovery. It grew from the convergence of several research streams over the past two decades — each of which independently demonstrated that biological ageing is not a fixed, inevitable trajectory but a dynamic process influenced by measurable and modifiable factors.

The Hallmarks of Ageing

In 2013, López-Otín and colleagues published a landmark paper in Cell identifying nine biological hallmarks of ageing — the cellular and molecular mechanisms through which organisms age. These included genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion and altered intercellular communication. A 2023 update expanded the hallmarks to twelve, adding disabled macroautophagy, chronic inflammation and dysbiosis.^[3] The clinical significance of this framework is profound: it identifies specific, measurable biological targets for lifestyle and therapeutic intervention — moving ageing from an inexorable process into an addressable clinical problem.

The Blue Zones — Real World Evidence

Concurrent with the laboratory research, National Geographic explorer Dan Buettner identified and documented populations around the world with significantly higher than average concentrations of centenarians and remarkably low rates of chronic disease — populations in Sardinia (Italy), Okinawa (Japan), Loma Linda (California), Nicoya (Costa Rica) and Ikaria (Greece).^[4] These became known as Blue Zones. Detailed epidemiological and ethnographic research in these communities identified shared lifestyle patterns — a plant-predominant diet, regular low-intensity natural movement, strong social connection, a sense of purpose, manageable stress and strong community belonging — that appeared to underpin their extraordinary healthspan.

The Scientific Momentum of Geroscience

The establishment of geroscience — the study of the relationship between biological ageing mechanisms and age-related disease — as a formal research discipline gave the longevity field its scientific foundation. The discovery that senolytic drugs (which clear senescent cells) extended healthspan in animal models, that caloric restriction consistently extended lifespan across multiple species, that NAD+ precursors restored mitochondrial function in aged tissues, and that rapamycin (an mTOR inhibitor) extended lifespan in mice even when given in late life — all generated enormous research interest and media coverage that accelerated public and clinical awareness.^[6]

The 2023 Netflix documentary Live to 100: Secrets of the Blue Zones and the 2023 publication of Peter Attia's Outlive brought longevity science directly into the public consciousness in a way no academic paper could. Both the public and practitioners began asking questions that functional medicine had been positioned to answer for decades: What drives early biological ageing? What can we do about it? And how much does it cost?

The Functional Medicine Framework for Longevity

Functional medicine has always been a longevity medicine — in the sense that its core principle of addressing upstream drivers of dysfunction to prevent chronic disease is identical to the core aim of extending healthspan. The formal longevity medicine movement has given this existing framework new language, new biomarkers and a growing research base, but the approach is recognisable to any functional medicine practitioner.

The Longevity Med Summit (2024, published in Frontiers in Aging) identified five core themes in contemporary longevity medicine: preventive medicine, diagnostics and biomarker assessment, personalised intervention, cellular and molecular biology of ageing, and societal determinants of healthy ageing.^[7] All five map directly onto functional medicine clinical practice.

The functional medicine approach to longevity is not primarily pharmaceutical. It is not predicated on rapamycin, senolytics or NMN supplementation — interventions with growing but still preliminary human evidence. It is predicated on the recognition that the hallmarks of ageing — telomere attrition, mitochondrial dysfunction, chronic inflammation, dysbiosis, cellular senescence — are all significantly modulated by lifestyle, and that the most powerful longevity interventions available to most patients today are, largely, free.

The Hallmarks of Ageing — What Practitioners Can Address

1. Telomere Attrition

Telomeres — the protective caps on chromosomal ends — shorten with each cell division and with oxidative stress and inflammation. Shorter telomeres are associated with earlier onset of age-related disease and shorter lifespan. A 2024 meta-analysis of randomised controlled trials (n=4,814 US adults) found that 90 minutes per week of strength training was associated with 3.9 years less biological ageing on average, measured by telomere length — one of the most striking longevity effects of any accessible intervention in the literature.^[8] A 2024 systematic review and meta-analysis in JMIR Public Health and Surveillance confirmed that physical exercise — particularly aerobic exercise and high-intensity interval training — has a significant positive effect on telomere length across RCTs, with HIIT showing the greatest effect compared with other exercise modalities.^[9]

2. Mitochondrial Dysfunction

Mitochondrial function declines with age, reducing cellular energy production and increasing reactive oxygen species (ROS) output — a key driver of oxidative stress and the ageing process. Aerobic exercise is the most evidence-based intervention for maintaining and restoring mitochondrial biogenesis and function, operating through PGC-1α activation. Resistance exercise, cold exposure and certain dietary patterns (particularly caloric restriction and time-restricted eating) also have documented effects on mitochondrial function through autophagy activation and AMPK signalling pathways.^[10]

3. Chronic Inflammation — Inflammageing

Chronic low-grade systemic inflammation — now termed "inflammageing" — is a consistent feature of biological ageing and a primary driver of age-related disease across virtually every organ system. Its drivers are modifiable: visceral adiposity, gut dysbiosis, oxidative stress, sleep insufficiency, psychological stress and a pro-inflammatory dietary pattern all contribute independently. The Mediterranean dietary pattern has the most robust evidence base for reducing systemic inflammatory markers, with multiple RCTs and a large evidence base from the PREDIMED trial demonstrating reductions in CRP, IL-6 and other inflammatory biomarkers.^[11]

4. Dysbiosis and the Gut Microbiome

The gut microbiome changes significantly with ageing — with reduced diversity, loss of keystone species including Faecalibacterium prausnitzii and Akkermansia muciniphila, and increased intestinal permeability. These changes contribute to inflammageing through LPS translocation and altered SCFA production. The microbiome is now recognised as a primary modifiable determinant of healthy ageing — and dietary fibre diversity, fermented food consumption and physical activity are all documented microbiome-supportive interventions available to patients at minimal cost.^[12]

5. Epigenetic Alterations — The Biological Clock

Epigenetic clocks — particularly the Horvath methylation clock and its successors — provide an estimate of biological age that frequently diverges from chronological age, with lifestyle factors being primary determinants of this divergence. Individuals with healthier lifestyles consistently show younger biological ages than their chronological age; those with chronic stress, poor sleep, inflammatory diets and sedentary behaviour show older biological ages. This means that biological ageing is not simply time passing — it is the cumulative effect of how we have lived, and it is partially reversible.^[13]

What Patients Can Do — The Evidence-Based, Low-Cost Approach

This is where functional medicine practitioners add irreplaceable value. The longevity supplement and pharmaceutical market is enormous — NMN, NAD+, rapamycin, senolytics, growth hormone protocols — and costs hundreds to thousands of euros per month. But the evidence base for these interventions in humans is, at this stage, preliminary. The evidence base for the lifestyle interventions below is, by contrast, robust, replicated and peer-reviewed. And most of them cost nothing.

Natural Movement — The NEAT Evidence

Blue Zone populations do not go to the gym. They live in environments that require constant low-level physical activity — tending gardens, walking to neighbours, doing household tasks without mechanical assistance. This is classified scientifically as NEAT: Non-Exercise Activity Thermogenesis. Studies demonstrate that NEAT contributes more to total daily energy expenditure than structured exercise in most people, and that sedentary behaviour is an independent risk factor for mortality — even in those who exercise regularly for 30–60 minutes per day but sit for the remaining hours.

Educating patients to reduce sitting time, walk after meals (a 10–15 minute post-prandial walk is documented to significantly reduce postprandial glucose and insulin), take the stairs, and generally increase incidental movement costs nothing and has substantial metabolic and longevity benefit.^[14]

The Role of Functional Testing in Longevity Assessment

While the lifestyle interventions above are available to all patients regardless of income, functional medicine practitioners can offer a deeper layer of longevity assessment through targeted testing that identifies an individual's specific biological ageing drivers:

• Biological age assessment — epigenetic clock testing (GlycanAge, TruAge) provides an estimate of biological vs chronological age, motivating patients and guiding intervention priorities
• Cardiovascular risk — advanced lipid panel — ApoB, Lp(a), oxidised LDL and hs-CRP provide a more complete cardiovascular longevity picture than standard lipid panels
• Metabolic function — fasting insulin, HOMA-IR, HbA1c and postprandial glucose assessment identify insulin resistance as a primary longevity risk factor years before diabetes diagnosis
• Inflammatory markers — hs-CRP, homocysteine, ferritin and IL-6 quantify inflammageing and guide anti-inflammatory intervention
• Nutritional status — vitamin D, magnesium, B12, omega-3 index and zinc — deficiencies in all of these are associated with accelerated biological ageing
• Gut microbiome assessment — comprehensive stool analysis identifies dysbiosis patterns and keystone species depletion driving inflammageing
• DEXA scan — muscle mass and bone density assessment, identifying sarcopenia risk before it becomes clinically apparent

What About the Supplements and Pharmaceuticals?

Patients will ask about NMN, NAD+, rapamycin, senolytics, metformin for longevity, resveratrol and growth hormone protocols. A brief, honest clinical framework:

• NAD+ precursors (NMN, NR) — human evidence for longevity benefit is currently limited to small studies showing improvements in NAD+ levels, metabolic markers and muscle function. No large RCTs of clinical endpoints exist yet. Promising, but premature to recommend as first-line.^[15]
• Rapamycin — the most consistent longevity drug in animal studies; a 2025 small human trial showed cardiovascular improvements in older adults, but long-term safety data in humans are insufficient for routine use outside research settings^[16]
• Metformin — the TAME (Targeting Aging with Metformin) trial is ongoing; observational data are promising but clinical evidence for longevity in non-diabetic adults is not yet established
• Vitamin D — the most evidence-based supplementation recommendation in the longevity context for Irish patients, given the 40–50% deficiency prevalence and well-documented roles in immune function, bone health, cardiovascular risk and all-cause mortality
• Omega-3 fatty acids — documented anti-inflammatory effects with reasonable human evidence for cardiovascular and cognitive longevity benefit at 2–4g EPA/DHA daily
• Magnesium — deficiency is widespread in Irish adults and is associated with impaired sleep, insulin resistance, elevated blood pressure and reduced mitochondrial function — all accelerators of biological ageing

The Functional Medicine Longevity Consultation — A Framework

A functional medicine longevity assessment is not a single blood panel. It is a structured clinical conversation that covers the patient's complete lifestyle architecture — sleep, movement, diet, stress, social connection, purpose — assessed against the backdrop of their individual biomarker data, family history and functional status. The goal is to identify the patient's specific modifiable longevity risk factors and prioritise the interventions most likely to close the healthspan gap for that individual.

Conclusion

The longevity medicine movement has given us the biological language to explain what functional medicine practitioners have always known: that chronic disease is not an inevitable consequence of ageing but largely the result of how we have lived — and that the same lifestyle factors that drive early disease are, in many cases, reversible drivers of biological ageing that respond to evidence-based intervention.

The most important clinical contribution practitioners can make to their patients' longevity is not prescribing an expensive supplement protocol. It is helping them understand — clearly, specifically and evidentially — why sleep matters at a cellular level, why sitting is slowly ageing them, why the diversity of their diet is more important than the category of it, why their social relationships are as biologically important as their blood pressure, and why finding purpose is not a luxury but a health behaviour with measurable consequences.

Most of the most powerful longevity interventions available today are free. Our job is to make sure our patients know that, understand why, and actually do them.